---
title: "12 Health Care Stocks Moving In Thursday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289464411.md"
description: "In Thursday's pre-market session, several healthcare stocks showed significant volatility. Gainers included Propanc Biopharma (+52.6%), 60 Degrees (+16.66%), and Quantum Cyber (+16.14%). Conversely, notable losers were Atossa Therapeutics (-26.1%), Purple Biotech (-23.46%), and Humacyte (-20.9%). The report highlights specific price movements and market capitalizations for these companies during the early trading hours."
datetime: "2026-06-11T12:05:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289464411.md)
  - [en](https://longbridge.com/en/news/289464411.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289464411.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Thursday's Pre-Market Session

### Gainers

-   **Propanc Biopharma** (NASDAQ:PPCB) stock rose 52.6% to $2.06 during Thursday's pre-market session. The market value of their outstanding shares is at $3.0 million.
-   **60 Degrees** (NASDAQ:SXTP) stock rose 16.66% to $1.61. The company's market cap stands at $3.6 million.
-   **Quantum Cyber** (NASDAQ:QUCY) shares rose 16.14% to $2.23. The market value of their outstanding shares is at $43.7 million.
-   **Silexion Therapeutics** (NASDAQ:SLXN) shares moved upwards by 13.39% to $3.47. The company's market cap stands at $1.2 million.
-   **Genenta Science** (NASDAQ:GNTA) stock increased by 11.53% to $1.84. The market value of their outstanding shares is at $38.6 million.
-   **CEL-SCI** (AMEX:CVM) shares rose 9.91% to $1.3. The company's market cap stands at $17.1 million.

### Losers

-   **Atossa Therapeutics** (NASDAQ:ATOS) stock fell 26.1% to $3.25 during Thursday's pre-market session. The company's market cap stands at $37.8 million.
-   **Purple Biotech** (NASDAQ:PPBT) stock decreased by 23.46% to $2.27. The market value of their outstanding shares is at $2.7 million.
-   **Humacyte** (NASDAQ:HUMA) shares decreased by 20.9% to $1.06. The company's market cap stands at $297.5 million.
-   **GlucoTrack** (NASDAQ:GCTK) shares decreased by 20.3% to $0.32. The company's market cap stands at $2.5 million.
-   **Aditxt** (NASDAQ:ADTX) shares decreased by 17.84% to $0.02.
-   **Basel Medical Group** (NASDAQ:BMGL) shares fell 14.04% to $0.5. The company's market cap stands at $11.0 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [PPCB.US](https://longbridge.com/en/quote/PPCB.US.md)
- [PPBT.US](https://longbridge.com/en/quote/PPBT.US.md)
- [SXTP.US](https://longbridge.com/en/quote/SXTP.US.md)
- [ATOS.US](https://longbridge.com/en/quote/ATOS.US.md)
- [HUMA.US](https://longbridge.com/en/quote/HUMA.US.md)
- [SXTPW.US](https://longbridge.com/en/quote/SXTPW.US.md)
- [QUCY.US](https://longbridge.com/en/quote/QUCY.US.md)
- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md)
- [CVM.US](https://longbridge.com/en/quote/CVM.US.md)
- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)
- [ADTX.US](https://longbridge.com/en/quote/ADTX.US.md)
- [BMGL.US](https://longbridge.com/en/quote/BMGL.US.md)
- [PPCBD.US](https://longbridge.com/en/quote/PPCBD.US.md)
- [MYNZ.US](https://longbridge.com/en/quote/MYNZ.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)
- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Humacyte says Phase 3 V007 trial results show ATEV tops fistula for hemodialysis access at one year](https://longbridge.com/en/news/296352370.md)
- [Humacyte director Keith Anthony Jones reports purchase of 10,000 common shares worth $6,930](https://longbridge.com/en/news/296648477.md)
- [22:00 ETHumacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA](https://longbridge.com/en/news/296662242.md)
- [Humacyte director Keith Anthony Jones acquires 30,000 shares worth $17,820](https://longbridge.com/en/news/296394198.md)
- [Propanc Biopharma plans first-in-human Phase 1b trial of PRP in up to 40 advanced solid tumor patients](https://longbridge.com/en/news/296229103.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**